Explores Alzheimer's disease, anxiety, pain, and the renin-angiotensin system, including the development of the first renin inhibitor for clinical treatment.
Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
Explores the opportunities and challenges of genomics in biotechnologies and biomedicine, focusing on the human genome, personalized medicine, and the genomics of sudden cardiac death.
